|
Cost-effectiveness analysis: controlled-release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-Combi) study |
Saito I, Fujikawa K, Saruta T, Tomita F, Kimura H, Nagakura T, Hiraoka T |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Saito I, Fujikawa K, Saruta T, Tomita F, Kimura H, Nagakura T, Hiraoka T. Cost-effectiveness analysis: controlled-release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-Combi) study. Hypertension Research 2008; 31(7): 1399-1405 Indexing Status Subject indexing assigned by NLM MeSH Amlodipine /administration & Cost-Benefit Analysis; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Humans; Hypertension /drug therapy /economics; Japan; Nifedipine /administration & Randomized Controlled Trials as Topic; Tetrazoles /administration & Valine /administration & Valsartan; derivatives; dosage /analogs & dosage /economics; dosage /economics; dosage /economics AccessionNumber 22009100015 Date bibliographic record published 31/03/2009 |
|
|
|